<SEC-DOCUMENT>0001640334-17-002170.txt : 20171013
<SEC-HEADER>0001640334-17-002170.hdr.sgml : 20171013
<ACCEPTANCE-DATETIME>20171013163519
ACCESSION NUMBER:		0001640334-17-002170
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20171013
DATE AS OF CHANGE:		20171013

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nemus Bioscience, Inc.
		CENTRAL INDEX KEY:			0001516551
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				450692882
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-216664
		FILM NUMBER:		171136872

	BUSINESS ADDRESS:	
		STREET 1:		600 ANTON BLVD, SUITE 1100
		CITY:			COSTA MESA
		STATE:			CA
		ZIP:			92626
		BUSINESS PHONE:		(949) 396-0330

	MAIL ADDRESS:	
		STREET 1:		600 ANTON BLVD, SUITE 1100
		CITY:			COSTA MESA
		STATE:			CA
		ZIP:			92626

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LOAD GUARD LOGISTICS, INC.
		DATE OF NAME CHANGE:	20121107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LOAD GUARD TRANSPORTATION, INC.
		DATE OF NAME CHANGE:	20110324
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>nmus_424b3.htm
<DESCRIPTION>424B3
<TEXT>
<html><head><title>nmus_424b3.htm</title></head><body style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><b> <p style="MARGIN: 0px" align="right">Filed pursuant to Rule 424(b)(3)</p> <p style="MARGIN: 0px" align="right">Registration Nos. 333-216664</p> <p style="MARGIN: 0px" align="right">333-206992</p> <p style="MARGIN: 0px" align="right">333-214761</p> <p style="MARGIN: 0px" align="right">333-215645</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="center">PROSPECTUS SUPPLEMENT NO. 4</p> <p style="MARGIN: 0px" align="center">(To Prospectus Dated March 23, 2017)</p> <p style="MARGIN: 0px" align="center"><img src="nmus_424b3img1.jpg"> </p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center">NEMUS BIOSCIENCE, INC.</p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center">Up to&nbsp;25,585,663&nbsp;Shares of Common Stock</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p></b> <p style="MARGIN: 0px" align="justify">This prospectus supplement no.&nbsp;4 supplements the prospectus dated March 23,&nbsp;2017 relating to the resale by the selling shareholders identified in the prospectus of up to 25,585,663 shares of our common stock, $0.001 par value, including (i) 3,800,000 shares of common stock, which equals the number of shares of common stock issuable upon the conversion of shares of our Series D convertible preferred stock, par value $0.001 per share (&#8220;Series D Preferred Stock&#8221;), (ii) 14,501,500 shares of common stock, which equals the number of shares of common stock issuable upon the conversion of shares of our Series B convertible preferred stock, par value $0.001 per share (&#8220;Series B Preferred Stock&#8221;) and 6,250,000 shares of common stock issuable upon exercise of the warrants which we sold to investors in a private placement on August 20, 2015, (iii) 241,663 shares of common stock which we sold to investors in a private placement on January 7, 2015 and (iv) 792,500 shares of common stock issuable upon exercise of warrants issued to our placement agents.</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px">This prospectus supplement incorporates into our prospectus the information contained in our attached Current Report on Form 8-K, which was filed with the Securities and Exchange Commission on&nbsp;October 13, 2017.</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">You should read this prospectus supplement in conjunction with the prospectus, including any supplements and amendments thereto. This prospectus supplement is qualified by reference to the prospectus except to the extent that the information in this prospectus supplement supersedes the information contained in the prospectus. This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the prospectus, including any supplements and amendments thereto.</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">You should understand the risks associated with investing in our common stock. Before making an investment, read the &#8220;Risk Factors,&#8221; which begin on page&nbsp;4 of the prospectus.</p><b> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p></b> <p style="MARGIN: 0px" align="center">The date of this prospectus supplement is&nbsp;October 13, 2017.</p> <p style="MARGIN: 0px" align="center">&nbsp;</p><b> <p style="MARGIN: 0px" align="center"> <table id="pagebreak35336208-4659-4104-918e-b8880d569f1e" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid"></td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr></table></b><tr><td>&nbsp;</td></tr> <p> <p style="MARGIN: 0px" align="left">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b><font size="3">UNITED STATES</font></b></p> <p style="MARGIN: 0px" align="center"><b><font size="3">SECURITIES AND EXCHANGE COMMISSION</font></b></p> <p style="MARGIN: 0px" align="center"><b><font size="3">WASHINGTON, D.C. 20549</font></b></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b><font size="5">FORM 8-K</font></b></p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b>CURRENT REPORT</b></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="center">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="center">Date of Report (Date of earliest event reported): <b>October 13, 2017</b></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="45%" align="center" border="0"> <tr height="15"> <td style="BORDER-BOTTOM: 1px solid"> <p style="MARGIN: 0px" align="center"><b><font size="5">Nemus Bioscience, Inc.</font></b></p></td></tr> <tr height="15"> <td> <p style="MARGIN: 0px" align="center">&nbsp;(Exact name of registrant as specified in its charter)</p></td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="85%" align="center" border="0"> <tr height="15"> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"> <p style="MARGIN: 0px" align="center"><b>Nevada</b></p></td> <td valign="top" width="5%"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"> <p style="MARGIN: 0px" align="center"><b>000-55136</b></p></td> <td valign="top" width="5%"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"> <p style="MARGIN: 0px" align="center"><b>45-0692882</b></p></td></tr> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px" align="center">(State or other jurisdiction</p> <p style="MARGIN: 0px" align="center">of incorporation)</p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">(Commission</p> <p style="MARGIN: 0px" align="center">File Number)</p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">&nbsp;(IRS Employer</p> <p style="MARGIN: 0px" align="center">Identification No.)</p></td></tr></table></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b><u>600 Anton Boulevard, Suite 1100, Costa Mesa, CA 92626</u></b></p> <p style="MARGIN: 0px" align="center">(Address of principal effective offices) (Zip Code)</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="center">Registrant's telephone number, including area code: <b>(949) 396-0330</b></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="center">______________________________________________</p> <p style="MARGIN: 0px" align="center">(Former name or former address, if changed since last report.)</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify"><font face="Wingdings">o </font>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify"><font face="Wingdings">o </font>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify"><font face="Wingdings">o </font>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify"><font face="Wingdings">o </font>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&nbsp;</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">Emerging growth company&nbsp;<font face="Wingdings">x</font></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <font face="Wingdings">x</font></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px"><b style="MARGIN: 0px"> <table id="pagebreakf31f5234-07ba-4b6b-bd9d-3ca39bf706fe" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"> <p style="MARGIN: 0px">Item 8.01. Other Events.</b></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">On October 13, 2017, Nemus Bioscience, Inc. (the &#8220;Company&#8221;) issued a press release, a copy of which is filed as Exhibit 99.1 to this report and is incorporated by reference herein.</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify"><b>Item 9.01 Financial Statement and Exhibits.</b></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">(d) Exhibits</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr height="15"> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="10%"> <p style="MARGIN: 0px" align="justify"><b>Exhibit </b><b>Numbe</b>r</p></td> <td valign="top" width="2%"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="bottom"> <p style="MARGIN: 0px" align="justify"><b>Description</b></p></td></tr> <tr height="15" bgcolor="#cceeff"> <td valign="top"> <p style="MARGIN: 0px" align="justify"><a href="nmus_ex991.htm">99.1</a></p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify"><a href="nmus_ex991.htm">Press release dated October 13, 2017</a></p></td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"><b style="MARGIN: 0px"> <table id="pagebreak4532baf2-7eca-44e9-bd24-6cbdb0aab0c8" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center"></td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table> <p style="MARGIN: 0px"> <p style="MARGIN: 0px">&nbsp;</p></b> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b>EXHIBIT INDEX</b></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr height="15"> <td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="10%"> <p style="MARGIN: 0px 0px 0px 0in"><b>Exhibit No.</b></p></td> <td width="2%"> <p style="MARGIN: 0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid" valign="bottom"> <p style="MARGIN: 0px 0px 0px 0in"><b>Description</b></p></td></tr> <tr height="15" bgcolor="#cceeff"> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in"><a href="nmus_ex991.htm">99.1</a></p></td> <td> <p style="MARGIN: 0px">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><a href="nmus_ex991.htm">Press release dated October 13, 2017</a></p></td></tr></table></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px"><b style="MARGIN: 0px"> <table id="pagebreak4a8ba174-5736-4234-b6d2-98a11cf0f7b8" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center"></td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table> <p style="MARGIN: 0px"> <p style="MARGIN: 0px">&nbsp;</p></b> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b>SIGNATURES</b></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top" colspan="2"> <p style="MARGIN: 0px" align="justify"><b>Nemus Bioscience, Inc.</b></p></td> <td valign="top"></td></tr> <tr height="15"> <td valign="top" width="50%"></td> <td valign="top" width="3%">&nbsp;</td> <td valign="top" width="35%"></td> <td valign="top" width="12%"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px" align="justify">Date: October 13, 2017 </p></td> <td> <p style="MARGIN: 0px" align="justify">By:</p></td> <td style="BORDER-BOTTOM: 1px solid"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><em>/s/ Brian Murphy</em></p></td> <td valign="top"></td></tr> <tr height="15"> <td valign="top"></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="bottom"> <p style="MARGIN: 0px" align="justify">Brian Murphy</p></td> <td valign="top"></td></tr> <tr height="15"> <td></td> <td> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td> <p style="MARGIN: 0px" align="justify">Chief Executive Officer</p></td> <td></td></tr></table></p> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in"> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="100%" align="center" border="0"> <tr> <td style="BORDER-BOTTOM: black 1px solid"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td></tr></table></p></BODY></html></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>nmus_ex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html><head><title>nmus_ex991.htm</title></head><body style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="right"><b>EXHIBIT 99.1</b></p> <p style="MARGIN: 0px" align="right">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><img src="nmus_ex991img2.jpg"></p> <p style="MARGIN: 0px 0px 0px 0in"> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b>NEMUS Bioscience Provides Further Update on Previously Announced $20 Million Schneider Financing</b></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"><b>Costa Mesa, Calif. (October 13, 2017) NEMUS Bioscience, Inc. </b>(OTCQB: NMUS) (the "Company") today announced a further update to its news release dated May 4, 2017 and July 11, 2017 with respect to the signing of a private placement with Schneider Finance LLC, an affiliate of Schneider Brothers Ltd, a global closed investment fund, for the sale of 1,000,000 shares of Series E Preferred Stock of the Company for gross proceeds of $20,000,000. As previously announced, SB Securities Ltd, an affiliate of Schneider Brothers Ltd, entered into a guaranty to the benefit of the Company that guarantees the payment of the $20,000,000 investment. </p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px">As of today, Schneider Finance LLC has failed to provide funding to close the transaction on July 10, 2017 as required under the securities purchase agreement and SB Securities Ltd has failed to pay the $20,000,000 within 90 days of notice of Schneider Finance LLC&#8217;s default, as required by the terms of the guaranty. The Company has engaged Haynes and Boone, LLP, an American Lawyer top 100 law firm, to advise the Company regarding, and enforce as appropriate, its legal rights related to Schneider Brothers and its affiliates failure to honor its obligations.</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px">Copies of the securities purchase agreement and the guaranty are available with the U.S. Securities and Exchange Commission (the SEC) as exhibits to the Company's Form 8-K, filed on May 4, 2017 and July 11, 2017, respectively.</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px">On August 11, the Company reported in its quarterly report for the period ended June 30, 2017 filed with the SEC on Form 10-Q that it had approximately $108,859 in cash on hand. The Company will continue its efforts to raise capital and pursue strategic alternatives to finance existing and future operations. There can be no assurance of success in its financing or strategic alternatives efforts. </p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px" align="justify"><b>FORWARD LOOKING STATEMENTS </b></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">Statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties, including statements about the timing of our near term, intermediate term and long term goals. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," "believes," "can," "challenge," "predictable" "will," or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of NEMUS&#8217; most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, NEMUS disclaims any intent or obligation to update these forward-looking statements.</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify"> <table id="pagebreak1553e57c-6558-4f35-90e8-4ba960f75aeb" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center"></td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px" align="justify"><b>ABOUT NEMUS BIOSCIENCE, INC. </b></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabinoid-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the potential adverse events. NEMUS' strategy will explore the use of natural and synthetic compounds, alone or in combination. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development. </p> <p style="MARGIN: 0px" align="justify">For more information, visit http://www.nemusbioscience.com.<u></u></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify"><b>CONTACTS: </b></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify"><b>NEMUS Investor and Media Relations</b></p> <p style="MARGIN: 0px" align="justify"><b>PCG Advisory Group</b></p> <p style="MARGIN: 0px" align="justify">Adam Holdsworth</p> <p style="MARGIN: 0px" align="justify">Email: adamh@pcgadvisory.com</p> <p style="MARGIN: 0px" align="justify">Phone: 646-862-4607</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px" align="justify"> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="100%" align="center" border="0"> <tr> <td style="BORDER-BOTTOM: black 1px solid"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p></BODY></html></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>nmus_ex991img2.jpg
<TEXT>
begin 644 nmus_ex991img2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !6 34# 2(  A$! Q$!_\0
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MX3US5O%]Q=V-C)+ R(%8=,A1FMZ<(P7+%61&-@Y026]S,^$P_P"*R'_7N_\
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>%%!,_B1VFBWTVIZ9'=/&D1;^%7W ?B11110:G__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>nmus_424b3img1.jpg
<TEXT>
begin 644 nmus_424b3img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !E ; # 2(  A$! Q$!_\0
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M>]9YAB)P:A%Z=R8*%N>*-0ZS/*GE7(2:%AAD8<&K26^AZ3HMUK=C8Q)<0H6
MQT-8/?%;6F102:7>0WC[()UV=:SR_&353ED] <>9:*YX_JNOZGJERUQ<W<I+
M'("L0![5I>%_$=Y:ZC#:7,C7%E<.(I(9#D8/%7M5^'&M6TVZSA6[MV.4=#CC
MWS5_P[X#N=.U"WU#7=MO#&X=8@=S,1S7T3E&,>:YYT:=1SL[G1:MHL.D6\C>
M$X5&H;OGQRP'?%=9X.?6'T-#K8VW.[OUQ[U!J-O%!9/?:>AWR]7'-4O#M[>M
M?"/<TD1^]N[5Q?6G"IR36YZ4(<K['77KF.TFD7JL9(_*OE[4KJ2[U*YFE8EW
MD.23GO7T]?\ .FW/_7)OY&OEFX_X^I?]\UZ*L]3BS&3T01RO#(LD;E70Y!7K
M7N_P\\7KKNG"TNG'VV 8;G[X]:\$K2T35I]$U6"^MV.8VRR^H[TSDPV(E3?D
M?4F>*R?$W_(LZE_UP;^5&A:S;:YI<-Y;N"KKDKZ&CQ-_R+.I?]<&_E2L>U*2
ME!M=CY@_B-=)X%_Y'+3_ /KI7-]ZZ/P'_P CGIW_ %TIL\6G_$1](C[@KRGX
MI^*;BTDCTBSE,99=\K#KCTKU4\)TYKY_^)Q)\97&2>$44CU,7-PIJQQK,S.6
M)+$]2>])R.M(.O3I7KWA#X;Z7?Z)!>ZB&EDF7=@-@ 4V>33A.H[(\BS1FO?E
M^%OAK_GV?_OX:4_"[PU_S[/_ -_#1H;_ %.MT/ !UKZ'^&__ ")5E^/\ZK?\
M*O\ #0_Y=G_"0UT^DZ7;Z/I\=E:@B%.@)S2T.O"T)TVW(XSXLZE/9Z#%#"[)
MY\FUF4]J\./6O9/C&/\ B4V7_76O&CUH./&2ESB=^M>H_"GQ+*EZ^CW,I=)!
MF$L<[2.U>75<TJ^?3=3MKR-L-$X;BF84*LH5$SZJ6G50TK4(M2TZ"[C8%94#
M<5>R,5)]$I*2NBI?W:6=I-<2'"QJ6)^E?-WB7Q!=>(-5EN)Y6,08B- >%&>*
M]6^*^N?8-$%A&V);H\XZA17B!X)%4>1CZSYN5"9JQ97,MG>Q7$,C(Z,,$&JU
M.3_6+]10<$&TU8^I=)E>YTJUFD^\T88_B*X3XP_\@&R_Z[_^RFNYT'_D!6?_
M %Q7^5<-\8O^0!9?]=__ &4U/4]RM_ /%*]5^#'_ !]ZC_N+_.O*:]6^#'_'
MWJ/^XO\ .J/,P?\ %1[%2&EI#TJ3W3R/XS]--^K5Y,#\U>L_&C[NF_[SUY*.
MM-'@XO\ BL]G^#__ "!;O_KK7:>)-6.C:'<7N,LBG;GUKC?@]SHMW_UUK:^)
M6?\ A#+@>XH/1I.U&YX3J>J76K7CW-U*SLYS@G@>PJE]*/H/PK?\&Z%'XA\1
M0V4KE8L,[;>I IZ'E7<YV1@9HS7OJ_"[PV1\UM(3Z^8:</A;X:_Y]7_[^&C0
MZ/JE4\ R:V_".?\ A,-)_P"OA?YU[*?A=X;_ .?9_P#OLU-9_#K0-/O(;VWM
MW$L#!T(<GD47+A@ZJ>IS?B/XG6FF:Q)#8V*7,T)*-,S;1D=ACJ*D\/\ B+2?
M&%TT5S;M9WN-QV/P_P"->=:_X5U31M4FADMII8C(2DH4G>,]3[UT/P[\+7\^
MM1WLL+P6\8.688W5S5:,9Q:DM]32G5K.JDUI<[ZSGT6QO=JK+(P; 9^0#]*N
M:O/'83C4;W4(X[$#.QOXOH*@;PHWVK=YX\LMGWKS+XF7=P?$?V)F;[/ @"+G
M@^]<F$IRNTU9'5B*OLX7L=R/BGX9+>0([@1'Y=WE?+^56O[)T[5K?^T-+O8_
M(898GH*\%Y(Q^F*[;X=&>[U6YTAI&%K=P/Y@4]#V(]*ZZ^%I5E:2.*EC9R?*
MT>A:9H-K?$O'J,,T:G#>2V:M:_KGAOP[%#9WP)/4(BY/U-4]'\-+X)AFDMI'
MNY)CC!XP*SO$W@6Y\5S1ZI#,()&7:T<G2N>AAJ%&7+%':Y3Y+Q6ITIU8W^B1
M76AG=$3C@<K^M9OBW78-&\-P3:E:+-=R';'&#CGU-9XT#6O#FA6UCH-U')<&
M3=,Q/\JF\?>&-1US0K2>/#WELO[Q%&-V1SBMXTX.;N[KL)RER-VU.(A^*.N1
MLJ&*T-LO_+$1<8^N:[VW\0RZQI$%[I<1B5N)%5<D'TKQR+0=6>X\E;"<R9QM
MV'K7K6BV>H>"O!;2+:-=7;OO:(=LT5\/&<;=3GPTZEWSG8QO<2>'I6N<^:86
MSD>U?,US_P ?4O\ OFOH_3=1N=5\+27=U:M;2O$V4/TKYQN?^/J7_?-;4X<L
M5$SS'5HB HJUIUNMWJ5M ^=DD@1L>]:'B;P]/X=U9K64$Q'F)_45H>=&#:YC
M6\"^+)?#VJ)'*Y-E.V)%)X!]17M7B">.X\*7\L;!E:W8AO7BOF8D]*]'\*^+
M3/X8U#1;R4F1;=_)=SUXZ4';AL2U%QD>;_Q&ND\!_P#(Y:=_UTKG#C.*Z/P%
M_P CGIW_ %TH9S4M:J]3Z1'W*^??B?\ \CG<?[B_RKZ"'W*^??B?_P CG<?[
MB_RI'J8W^&CC5KV#P]\3=$TS0[2TG%R9(D"MM3BO'AUHZ]*9Y=&K.DVXGNO_
M  M[P]Z7?_?O_P"O1_PM[P]_=NO^_?\ ]>O"J.:#I6,K'N;?%SP^W\%T?^V=
M=OIUY%J%A#=Q B.90ZY'.#7RL,XKZ9\)_P#(K:8/^F"T'9A*U2I?F.,^,?\
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MSR??3ZBNA\=?\CIJ?_77^@KGD^^GU%(Y*G\5GU%H/_($LO\ KBG\JX7XR?\
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M!_\ /M:?41FMW1]9T-F2PTUT4#[J(I %(Z</0]D]6<?\8_\ D%6.>,RFO&B
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<_@==%X;N]5OEDFOKV&15. D<&S]=QHHI$4C_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
